GKOS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Glaukos Corporation

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
CEO
Thomas Burns
Employees
653
Headquarters

229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com

News

Glaukos corp executive sells over $6 million in company stock
Apr 11, 2024 00:24am

https://www.investing.com/news/company-news/glaukos-corp-executive-sells-over-6-million-in-company-stock-93CH-3374099


Source:Investing.com
Glaukos Corp CFO Alex Thurman Sells Company Shares
Apr 10, 2024 05:50am

Glaukos Corp CFO Alex Thurman Sells Company Shares


Source:GuruFocus
Glaukos Corp president & COO sells $38.6k in stock
Apr 05, 2024 22:18pm

https://www.investing.com/news/company-news/glaukos-corp-president--coo-sells-386k-in-stock-93CH-3368310


Source:Investing.com
Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant)
Apr 03, 2024 11:00am

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose TR (travoprost intracameral implant) Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Apr 01, 2024 11:00am

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Celanese Announces Commercial Launch of Glaukos'' iDose TR (Travoprost Intracameral Implant) Using Celanese''s VitalDose Ethylene Vinyl Acetate (EVA)
Feb 29, 2024 14:00pm

Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, announced the launch of iDose TR by Glaukos Corporation using Celanese’s VitalDose EVA to provide sustained drug release for the treatment of glaucoma. The majority of glaucoma and ocular hypertension patients are non-compliant with topical medication use due to complex dosing regiments, side effects, and eye-drop Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Celanese Announces Commercial Launch of Glaukos''; iDose® TR (Travoprost Intracameral Implant) Using Celanese''s VitalDose® Ethylene Vinyl Acetate (EVA) | CE Stock News
Feb 29, 2024 14:00pm

Celanese Corporation collaborates with Glaukos Corporation to launch iDose® TR, a sustained drug release system for glaucoma treatment. The FDA-approved iDose® TR uses Celanese''s VitalDose® EVA to deliver continuous dosing of travoprost, improving patient compliance and treatment outcomes.


Source:Stock Titan
Glaukos to Present Periodic Investor Updates Online
Feb 28, 2024 12:13pm

Glaukos (GKOS) has shared an announcement. Glaukos Corporation is set to share an Investor Presentation periodically to engage investors and stakeh…


Source:TipRanks
Glaukos Corp Director Mark Foley Sells 4,560 Shares
Feb 27, 2024 07:03am

Glaukos Corp Director Mark Foley Sells 4,560 Shares


Source:GuruFocus
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Feb 22, 2024 12:23pm

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Piper Sandler raised the price target for Wix.com Ltd. (NASDAQ: WIX ) from $146 to $165. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Wix.com shares rose 5.9% to close at $132.77 on Thursday. See how other analysts view this stock. Keybanc boosted Analog Devices, Inc. (NASDAQ: ADI ) price target from $220 to $230. Keybanc analyst John Vinh maintained an Overweight rating. Analog Devices shares gained 2.3% to close at $193.72 on Wednesday. See how other analysts view this stock. Needham raised the price target for Glaukos Corporation (NYSE: GKOS ) from $105 to $108. Needham analyst David Saxon maintained a Buy rating. Glaukos shares rose 0.7% to close at $92.79 on Wednesday. See how other analysts view this stock . TD Cowen raised Wingstop Inc. (NASDAQ: WING ) … Full story available on Benzinga.


Source:Benzinga